A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee

NCT00981357

Last updated date
Study Location
Arthritis & Rheumatic Care Center
Miami, Florida, 33143, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Knee Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray

- Subjects must be willing and able to stop all current pain therapy for the duration of study. (Limited and specific pain therapy will be available throughout the study)

- Subjects can be male or female between the ages of 18 and 75 years inclusive, but female subjects must not be able become pregnant

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects must not have any condition or medical history that might interfere with
their ability to complete the study assessments

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Knee OsteoarthritisA Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
NCT00650624
  1. Funabashi, Chiba
  2. Sakura, Chiba
  3. Chikushi-gun, Fukuoka
  4. Iizuka, Fukuoka
  5. Kurume, Fukuoka
  6. Yame, Fukuoka
  7. Chitose, Hokkaido
  8. Sapporo, Hokkaido
  9. Kamakura, Kanagawa
  10. Yokohama, Kanagawa
  11. Isahaya, Nagasaki
  12. Hirakata, Osaka
  13. Kanzaki-gun, Saga
  14. Karatsu, Saga
  15. Ogi-gun, Saga
  16. Itabashi-ku, Tokyo
  17. Setagaya-ku, Tokyo
  18. Shinjuku-Ku, Tokyo
  19. Taito-ku, Tokyo
  20. Yoyogi Shibuya-ku, Tokyo
  21. Saga,
  22. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Knee OsteoarthritisEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)
NCT00630929
  1. Bad Muender,
  2. Beckum,
  3. Berlin,
  4. Berlin,
  5. Berlin,
  6. Berlin,
  7. Ostseebad Damp,
  8. Schwerin,
  9. Stade,
  10. Tostedt,
  11. Weener,
  12. Barcelona,
  13. Barcelona,
  14. Cadiz,
  15. Guadalajara,
  16. Madrid,
  17. Madrid,
  18. Madrid,
  19. Oviedo,
  20. Sevilla,
  21. Valencia,
  22. Chelmsly Wood, Birmingham
  23. Truro, Cornwall
  24. Chorley, Lancs
  25. Liverpool, Lancs
  26. Cannock, Mid Staffordshire
  27. Addlestone, Surrey
  28. Huddersfield,
  29. London,
  30. London,
  31. Manchester,
  32. Newcastle Upon Tyne,
  33. Wigan,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Knee OsteoarthritisA Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee
NCT00981357
  1. Miami, Florida
  2. Miami, Florida
  3. Overland Park, Kansas
  4. Overland Park, Kansas
  5. San Antonio, Texas
  6. Sherbrooke, Quebec
  7. Goteborg,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Knee OsteoarthritisSafety and Efficacy of Celecoxib Versus Naproxen in the 6-Month Treatment of Knee Osteoarthritis
NCT00643799
  1. Montgomery, Alabama
  2. Phoenix, Arizona
  3. Tempe, Arizona
  4. Buena Park, California
  5. Paramount, California
  6. Rancho Mirage, California
  7. San Diego, California
  8. San Diego, California
  9. Denver, Colorado
  10. Washington, District of Columbia
  11. Clearwater, Florida
  12. Deland, Florida
  13. Jacksonville, Florida
  14. Miami, Florida
  15. Ocala, Florida
  16. Orlando, Florida
  17. Pembroke Pines, Florida
  18. Tampa, Florida
  19. Zephyrhills, Florida
  20. Rockford, Illinois
  21. Wichita, Kansas
  22. Wichita, Kansas
  23. Lexington, Kentucky
  24. Lexington, Kentucky
  25. Covington, Louisiana
  26. Metairie, Louisiana
  27. Clinton, Maryland
  28. Greenbelt, Maryland
  29. Hagerstown, Maryland
  30. Wheaton, Maryland
  31. Milford, Massachusetts
  32. Lansing, Michigan
  33. Flowood, Mississippi
  34. Kansas City, Missouri
  35. Lincoln, Nebraska
  36. Lincoln, Nebraska
  37. New York, New York
  38. Beachwood, Ohio
  39. Columbus, Ohio
  40. Columbus, Ohio
  41. Columbus, Ohio
  42. Oklahoma City, Oklahoma
  43. Bethlehem, Pennsylvania
  44. Duncansville, Pennsylvania
  45. Media, Pennsylvania
  46. Warwick, Rhode Island
  47. Austin, Texas
  48. Dallas, Texas
  49. San Angelo, Texas
  50. Salt Lake City, Utah
  51. Salt Lake City, Utah
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee
Official Title  ICMJE A Phase 2a Randomized, Double-blinded, Double Dummy, Placebo And Active Controlled, Two-way Cross-over, Flare-enriched Multi-centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A Fatty Acid Amide Hydrolase (Faah) Inhibitor Pf-04457845 In Patients With Osteoarthritis Of The Knee.
Brief Summary Inactivation of the FAAH (Fatty Acid Amide Hydrolase) enzyme has been shown to relieve pain and inflammation in animal studies. PF-04457845 has been shown to inactivate the FAAH enzyme in animals and healthy human volunteers. The purpose of this study is to evaluate whether PF-04457845 can inactivate the FAAH enzyme in patients experiencing pain due to OA and whether this results in these patients experiencing less pain.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis, Knee
Intervention  ICMJE
  • Drug: PF-04457845
    PF-04457845 4 mg tablet once daily / matched placebo
  • Drug: Naproxen
    Naproxen 500 mg tablet twice daily / matched placebo
Study Arms  ICMJE
  • Experimental: PF-04457845 followed by placebo
    Intervention: Drug: PF-04457845
  • Experimental: Placebo followed by PF-04457845
    Intervention: Drug: PF-04457845
  • Active Comparator: Naproxen followed by placebo
    Intervention: Drug: Naproxen
  • Active Comparator: Placebo followed by Naproxen
    Intervention: Drug: Naproxen
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 30, 2010)
76
Original Estimated Enrollment  ICMJE
 (submitted: September 21, 2009)
130
Actual Study Completion Date  ICMJE May 2010
Actual Primary Completion Date May 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray
  • Subjects must be willing and able to stop all current pain therapy for the duration of study. (Limited and specific pain therapy will be available throughout the study)
  • Subjects can be male or female between the ages of 18 and 75 years inclusive, but female subjects must not be able become pregnant

Exclusion Criteria:

  • Subjects must not have any condition or medical history that might interfere with their ability to complete the study assessments
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Sweden,   United States
Removed Location Countries South Africa
 
Administrative Information
NCT Number  ICMJE NCT00981357
Other Study ID Numbers  ICMJE B0541004
2009-014734-16 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP